Trial Profile

An Open-label Study to Assess the Efficacy and Safety of Extended TARPEYO (Delayed-release Budesonide Capsules) Treatment in Adult Patients With Primary IgA Nephropathy Who Have Completed 9 Months of TARPEYO 16 mg Once Daily Treatment in Real-world Clinical Practice

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Jun 2025 According to Calliditas Therapeutics media release, data from this trial presented at the 62nd European Renal Association Congress (ERA Congress)
13 Feb 2025 Status changed from not yet recruiting to recruiting.
09 Dec 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com